Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.

TitleCost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Publication TypeJournal Article
Year of Publication2013
AuthorsKleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, Asukai Y, Saka Ö, Evers T, Faes P, Vansieleghem S, De Ruyck M
JournalPharmacoEconomics
Volume31
Issue10
Pagination909-18
Date Published2013 Oct
Abstract

Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages over warfarin, the standard of care in a world without NOACs, has been introduced and is now recommended by international guidelines.

DOI10.3402/iee.v3i0.21356
Alternate JournalPharmacoeconomics